Caplacizumab treatment in elderly patients with iTTP: Experience from the Spanish TTP Registry.
Inés Gómez-Seguí, Joan Cid, Miquel Lozano, Maria Eva Mingot-Castellano, Cristina Pascual-Izquierdo, Luz Maria Gonzalez Del Castillo, Julia Maria Vidan Estevez, Faustino Garcia-Candel, Moraima Jiménez Balarezo, David Valcarcel and 11 more
Article in HemaSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Miquel LozanoHospital Clínic de Barcelona, Apheresis Unit Barcelona Spain.
Maria Eva Mingot-CastellanoDepartment of Hematology and Hemotherapy Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC) Universidad de Sevilla Sevilla Spain.
Cristina Pascual-IzquierdoDepartment of Hematology and Hemotherapy Hospital Gregorio Marañón Madrid Spain.
Luz Maria Gonzalez Del CastilloDepartment of Hematology and Hemotherapy Hospital Dr. Negrín, Las Palmas de Gran Canaria Spain.
Julia Maria Vidan EstevezDepartment of Hematology and Hemotherapy Hospital de León León Spain.
Faustino Garcia-CandelDepartment of Hematology and Hemotherapy Hospital Virgen de la Arrixaca Murcia Spain.
Moraima Jiménez BalarezoDepartment of Hematology and Hemotherapy Hospital Vall d'Hebrón Barcelona Spain.
David ValcarcelDepartment of Hematology and Hemotherapy Hospital Vall d'Hebrón Barcelona Spain.
Clara Cuellar Perez-AvilaDepartment of Hematology and Hemotherapy Hospital 12 de Octubre Madrid Spain.
Maria Arraiz RamirezDepartment of Hematology and Hemotherapy Hospital de Donostia Gipuzkoa Spain.
Sunil LakhwaniDepartment of Hematology and Hemotherapy Hospital Universitario de Canarias La Laguna Santa Cruz de Tenerife Spain.ORCID 0000-0003-1984-4839
Maria Gemma Moreno JimenezDepartment of Hematology and Hemotherapy Hospital Ramón y Cajal Madrid Spain.
Ana Yurena Oliva HernandezDepartment of Hematology and Hemotherapy Hospital Na. Sra. de Candelaria Santa Cruz de Tenerife Spain.
Jose Maria Garcia GalaDepartment of Hematology and Hemotherapy Hospital Central de Asturias Oviedo Spain.
Jorge Martinez NietoDepartment of Hematology and Hemotherapy Hospital Clínico San Carlos Madrid Spain.
Rosa GoterrisDepartment of Hematology and Hemotherapy Hospital Clínico de Valencia Valencia Spain.
Marta Fernández DocampoDepartment of Hematology and Hemotherapy Complexo Hospitalario Universitario A Coruña A Coruña Spain.
Clara Sopeña Pell-IldertonDepartment of Hematology and Hemotherapy La Fe University and Polytechnic Hospital Valencia Spain.
Javier de la RubiaDepartment of Hematology and Hemotherapy La Fe University and Polytechnic Hospital Valencia Spain.ORCID 0000-0002-8354-768X
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Immune thrombotic thrombocytopenic purpura (iTTP) typically affects middle-aged individuals, although it sometimes appears in older patients. Caplacizumab is approved for the treatment of iTTP, but information on the safety and efficacy of this drug in elderly patients is not available. We aimed to analyze the management and outcomes of iTTP patients registered in the Spanish TTP Registry and receiving caplacizumab at any time during the acute episode, focusing on patients ≥60 years (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Caplacizumab treatment in elderly patients with iTTP: Experience from the Spanish TTP Registry. · full record | OpenQuestion